The series hosts a seminar every other week on current research topics. The seminar often features an invited guest speaker and occasionally local faculty members, students or others affiliated with the department. The usual time of the seminar is 11-12 pm on Fridays. Professors Joseph Gastwirth (E-mail: firstname.lastname@example.org) and Tatiyana V Apanasovich (E-mail: email@example.com) are the Seminar Series Coordinators.
Department Seminars in Fall 2012
Date & Time: Fri, Nov, 15, 11am-12pm
Place: Duques Hall, Room 152 (2201 G St NW)
Speaker: Nancy L. Geller, Office of the Biostatistics Research, National Heart, Lung and Blood Institute
Title: Has the time come to give up blinding in randomized clinical trials?
ABTRACT: Should all trials be double blinded, that is, should treatment allocation be concealed from both the subjects and those administering the treatment? In the late 1980's and early1990's trialists advocated strongly for double blinding of clinical trials, yet in the past 15 years, we have seen more and more clinical trials that are unblinded. While it is relatively easy to make a placebo controlled trial of a medication given orally double blinded, reasons for not blinding include that in some situations it is too difficult (or expensive) to blind, in some situations, it may be unethical to blind and in other situations, it is impossible to blind. Complex interventions may make blinding especially difficult. Comparative effectiveness studies also encourage unblinded trials because “blinding is not done in the real world.” We give several examples of recent trials which have not been blinded and examine the consequences.